PATENT CLAIM ANALYSIS

Application Number: 15874662
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-11
Patent Classification: ["514", "04400A"]

Abstract:
Provided herein are improved compounds, compositions and associated methods for reducing expression of ApoCIII mRNA and protein in a subject having, or at risk of having, diabetes. Also provided herein are compounds, compositions and associated methods improving peripheral insulin sensitivity, a lipid profile and a diabetes profile as well as reducing free fatty acids and intramyocellular triglyceride deposition.

Claim (Index 7):
The method of  claim 1 , wherein the subject has fasting triglyceride levels \u2265200 and \u2264500 mg/dl.

Metadata:
- Claim Count in Document: 65.0
- Percentile: 86.0
- Lexical Diversity: 1.54762
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14900320', '14768180', '14114187', '14149715', '13520997']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8378526927234322
- 35 USC 102 Novelty (BERT): 0.6246145293432185
- Combined Prediction Score: 0.8165288763854108
- Mean Citation Score: 514.4663099999998
- Max Citation Score: 572.3476
- Similarity Product: 545.1963552834511

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test